Literature DB >> 15773788

Radiation-enhanced endostatin gene expression and effects of combination treatment.

Xian Luo1, Melba L Andres, Tatyana M Timiryasova, Istvan Fodor, James M Slater, Daila S Gridley.   

Abstract

Targeting cells that support tumor growth by administering potent angiogenesis inhibitors is currently an area of intense interest. In the present study, a unique plasmid vector for the mouse endostatin gene, pXLG-mEndo, was constructed and evaluated with and without radiation using the Lewis lung carcinoma (LLC) cell line. The physical properties of the expressed endostatin protein were validated by PCR, gel electrophoresis, and Western blot. Enzyme-linked immunosorbent and immunocytochemical analyses for the therapeutic gene demonstrated that transfected LLC cells secreted the protein into the medium. Exposure of the cells to 2 gray (Gy) gamma-rays reduced the time to reach the maximum expression level of the endostatin gene and also increased the amount of secreted endostatin protein (P<0.001). Biological activity of the endostatin was demonstrated by the inhibition of tube formation by human umbilical vein endothelial cells (HUVEC). Based on (3)H-thymidine incorporation, endostatin expression significantly depressed DNA synthesis in HUVEC and LLC cells compared to controls transfected with parental vector or no vector (P<0.005). In addition, radiation increased the efficiency of endostatin-mediated inhibition of both cell types over a 3-day period post-exposure (P<0.05 or less). Intratumoral injection of 100 small mu g pXLG-mEndo combined with 10 Gy radiation significantly delayed LLC tumor growth, especially when each modality was delivered twice (P<0.05 or less compared to all other groups). No toxicity was observed. These findings are very promising and suggest that endostatin therapy with a plasmid vector, such as pXLG-mEndo, may enhance the efficacy of radiotherapy for lung cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15773788     DOI: 10.1177/153303460500400208

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  6 in total

1.  Preliminary clinical study of weekly recombinant human endostatin as a hypoxic tumour cell radiosensitiser combined with radiotherapy in the treatment of NSCLC.

Authors:  Xiao-Dong Jiang; Yun Qiao; Peng Dai; Jin Wu; Da-An Song; Shi-Qiu Li; Yue-Wei Fan
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

2.  Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer.

Authors:  Xiao-Dong Jiang; Peng Dai; Yun Qiao; Jin Wu; Da-An Song; Shi-Qiu Li
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

3.  Updating advances on recombinant human endostatin combined with radiotherapy for non-small cell lung cancer with brain metastasis.

Authors:  Xiao-Dong Jiang; Yun Qiao
Journal:  Transl Lung Cancer Res       Date:  2012-03

Review 4.  Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature.

Authors:  Dan-Fang Yan; Sen-Xiang Yan; Jing-Song Yang; Yi-Xiang J Wang; Xiao-Li Sun; Xin-Biao Liao; Jun-Qing Liu
Journal:  BMC Cancer       Date:  2010-02-21       Impact factor: 4.430

5.  Enhancement of recombinant human endostatin on the radiosensitivity of human pulmonary adenocarcinoma A549 cells and its mechanism.

Authors:  Xiao-dong Jiang; Yun Qiao; Peng Dai; Qin Chen; Jin Wu; Da-an Song; Shi-qiu Li
Journal:  J Biomed Biotechnol       Date:  2012-06-18

6.  Antitumor activities of human placenta-derived mesenchymal stem cells expressing endostatin on ovarian cancer.

Authors:  Lan Zheng; Dongmei Zhang; Xiancheng Chen; Li Yang; Yuquan Wei; Xia Zhao
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.